 |
|
|
| |
SVR12 Rate of 98.6% in 992 HCV Genotype 1b-Infected Patients Treated With ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin
|
| |
| |
Reported by Jules Levin
AASLD 2014 Boston Nov 7-11
Massimo G Colombo1, Ola Weiland2, Daniel E Cohen3, Jean-Francois DuFour4, Hendrik Reynaert5, Moisés Diago6, Erica Villa7, Adrian Streinu-Cercel8, Wangang Xie3, Jeff rey V Enejosa3, Eoin Coakley3,
Roger Trinh3, Thomas Podsadecki3
1Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy; 2Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden; 3AbbVie Inc., North Chicago, Illinois, United States; 4Inselspital Bern, Bern, Switzerland;
5Universitair Ziekenhuis Brussels, Brussels, Belgium; 6Hospital Quiron de Valencia, Valencia, Spain; 7AOU Policlinico di Modena, Modena, Italy; 8Carol Davila University of Medicine and Pharmacy, National Institute for Infectious Diseases "Prof. Dr. Matei Bals," Bucharest, Romania
|
| |
|
|
|
|
|
